CytoPharm and Amarillo Biosciences (AMAR) Announce Positive HCV Study Results: Oral Interferon Found to Reverse Thrombocytopenia; Reduced Relapse Rate Seen in Patients With Mild Fibrosis
6/15/2012 7:50:48 AM
More...
|
Amarillo Biosciences (AMAR) and CytoPharm Announce Start of Enrollment for Hepatitis C Study in Taiwan
6/29/2009 10:59:20 AM
More...
|
Amarillo Biosciences (AMAR) Partner CytoPharm Approved to Enroll 165 Patient Phase 2 Hepatitis C Trial in Taiwan
2/13/2009 9:52:49 AM
More...
|
Amarillo Biosciences (AMAR) Signs Deal with CytoPharm of Taiwan
3/25/2008 1:28:38 PM
More...
|
Amarillo Biosciences (AMAR) Enters Into a License and Supply Agreement With CytoPharm for Low Dose Oral Interferon Use in Animal Diseases in China and Taiwan
3/25/2008 9:56:34 AM
More...
|
Amarillo Biosciences (AMAR) Partner, CytoPharm, to Conduct 144 Patient Phase 2 Hepatitis C Trial in Taiwan
2/19/2008 10:16:07 AM
More...
|
CytoPharm to Conduct Hepatitis C Trial and Seek Regulatory Approval for Amarillo Biosciences (AMAR)' Low Dose Oral Interferon
5/31/2007 1:05:33 PM
More...
|